The microbiome and systemic sclerosis: A review of current evidence.
Gastrointestinal
Microbiome
Microbiota
Scleroderma
Systemic sclerosis
Journal
Best practice & research. Clinical rheumatology
ISSN: 1532-1770
Titre abrégé: Best Pract Res Clin Rheumatol
Pays: Netherlands
ID NLM: 101121149
Informations de publication
Date de publication:
09 2021
09 2021
Historique:
pubmed:
15
4
2021
medline:
3
11
2021
entrez:
14
4
2021
Statut:
ppublish
Résumé
Systemic sclerosis (SSc) is characterized by immune dysregulation, vasculopathy, and fibrosis of multiple organs. The gastrointestinal (GI) tract is the most common internal organ manifestation, which contributes to significant morbidity and mortality in patients with SSc. Emerging reports have identified unique microbial taxa alterations in the GI microbiome of patients with SSc as compared to healthy controls (HC). These taxa alterations include differences at the phyla (e.g., Bacteroidetes) and genera (e.g., Bacteroides, Clostridium, Faecalibacterium, and Lactobacillus) level. In addition, some genera have been associated with more severe GI symptoms (e.g., Prevotella and Akkermansia). This review summarizes the current evidence on factors influencing the GI microbiome, GI microbiome alterations in SSc as compared to HC, and in SSc subgroups according to disease manifestations. Current exploration in therapeutic interventions that target the GI microbiome is discussed.
Identifiants
pubmed: 33849778
pii: S1521-6942(21)00029-2
doi: 10.1016/j.berh.2021.101687
pii:
doi:
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
101687Informations de copyright
Copyright © 2021 Elsevier Ltd. All rights reserved.
Déclaration de conflit d'intérêts
Declaration of competing interest The authors do not have any conflicts of interest to declare.